Eli Lilly announced positive Phase 3 BRUIN CLL-322 study results showing that adding pirtobrutinib to venetoclax and rituximab significantly improves progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). This is the first Phase 3 trial in CLL to outperform a venetoclax-based regimen. Lilly will also present early clinical data from Ajax Therapeutics and Kelonia Therapeutics, companies it plans to acquire, highlighting new treatments for myelofibrosis and multiple myeloma. These developments strengthen Lilly's hematology portfolio and offer hope for better blood cancer therapies.
Wells Fargo's economist forecasts GLP-1 weight-loss drugs like Ozempic and Mounjaro will reach about 90 million prescriptions, rivaling statins. This trend is driving demand for high-protein, low-volume foods suited for appetite-suppressed patients, ...
In the first half of 2026, smart beta strategies showed mixed results, with momentum and low-volatility funds lagging, while dividend growth funds struggled due to rising yields. However, funds emphasizing companies with strong free cash flow and hig...
A list of the top 25 high-growth dividend stocks for June 2026 highlights quality companies trading about 30% below intrinsic value, with an average dividend yield of 1.50% and a five-year dividend growth rate of 17.61%. The basket is estimated to de...
Eli Lilly has exercised its option to include amylin receptor agonists in its collaboration with Camurus, extending its exclusive global rights to Camurus' FluidCrystal technology. This expands Lilly's development and commercialization efforts to cov...
Eli Lilly announced that the Phase 3 LIBRETTO-432 trial of Retevmo (selpercatinib) significantly improved event-free survival by reducing the risk of recurrence or death by 83% compared to placebo in early-stage RET fusion-positive non-small cell lun...
